Company Filing History:
Years Active: 2001-2004
Title: Christopher Turchik Jagoe: Innovator in Cancer Treatment
Introduction
Christopher Turchik Jagoe is a notable inventor based in Chatham, NJ (US). He has made significant contributions to the field of cancer treatment, holding a total of 3 patents. His work focuses on innovative methods to combat drug-resistant cancer cells, showcasing his commitment to advancing medical science.
Latest Patents
Jagoe's latest patents include a method for treating cells resistant to antineoplastic agents. This invention relates to methods for treating multidrug resistant cells, particularly cancer cells, using discodermolide. Discodermolide has been found effective in limiting the growth of otherwise unregulated cells with tubulin mutations and in promoting phosphorylation of the oncogene RAF-1. Another significant patent involves the use of certain substituted caprolactams in treating tumors. This invention details specific caprolactam compounds, their pharmaceutical compositions, and their application in tumor treatment.
Career Highlights
Christopher Turchik Jagoe is currently associated with Novartis AG, a leading global healthcare company. His role at Novartis allows him to collaborate with other experts in the field and contribute to groundbreaking research in oncology.
Collaborations
Jagoe has worked alongside notable colleagues such as Frederick Ray Kinder, Jr. and Kenneth Walter Bair. These collaborations have further enriched his research and development efforts in cancer treatment.
Conclusion
Christopher Turchik Jagoe is a dedicated inventor whose work in cancer treatment is making a significant impact. His innovative patents and collaborations reflect his commitment to improving patient outcomes in the fight against cancer.